PolyMedix PYMX has
scheduled a conference call and webcast for Wednesday, December 7 at 9:00 AM
Eastern Time. At that time, management will review the results of the interim
analysis from the ongoing Phase 2 clinical study with PMX-30063,
defensin-mimetic antibiotic in treating patients with Staph Acute Bacterial
Skin and Skin Structure Infections. This is the first clinical study
ever conducted in patients with Staph infections with this new class of
antibiotic – a defensin-mimetic.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in